Mireia Atance, Cristina Serrano, Carlos Soto, Juan Manuel Alonso-Domínguez, Carlos Blas, Raquel Mata, Tamara Castaño, Sara Perlado, Teresa Arquero, Jose Luis López-Lorenzo, M. Ángeles Pérez, Belen Rosado, Rafael Martos, Ana Rio-Machin, Pilar Llamas-Sillero, Rocio N. Salgado, Juana Serrano-López
{"title":"Flow Cytometry Analysis of Mesenchymal Stem Cells: A Predictive Biomarker for Leukemia Transformation in Myelodysplastic Syndrome","authors":"Mireia Atance, Cristina Serrano, Carlos Soto, Juan Manuel Alonso-Domínguez, Carlos Blas, Raquel Mata, Tamara Castaño, Sara Perlado, Teresa Arquero, Jose Luis López-Lorenzo, M. Ángeles Pérez, Belen Rosado, Rafael Martos, Ana Rio-Machin, Pilar Llamas-Sillero, Rocio N. Salgado, Juana Serrano-López","doi":"10.1002/jha2.70059","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study evaluates the prognostic value of bone marrow-derived mesenchymal stem cells (MSCs) in predicting the progression of Myelodysplastic Syndrome (MDS) to Acute Myeloid Leukemia (AML).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>MSC-like cells were analyzed using flow cytometry in a cohort of 49 MDS patients, including transformed and non-transformed groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A non-hematopoietic CD13-bright cell population, enriched for MSC markers CD105 and CD90, was identified in 80% of patients at diagnosis. Elevated of these MSC-like cells were significantly associated with earlier progression to leukemia and reduced overall survival. Multivariate analysis confirmed MSC content as an independent predictor of leukemia transformation.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>MSC-like cell content at MDS diagnosis may serve as a novel biomarker of predicting malignant transformation to AML. Further validation in larger cohorts and better phenotypic characterization of this cell population are needed.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>The authors have confirmed clinical trial registration is not needed for this submission</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70059","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
This study evaluates the prognostic value of bone marrow-derived mesenchymal stem cells (MSCs) in predicting the progression of Myelodysplastic Syndrome (MDS) to Acute Myeloid Leukemia (AML).
Methods
MSC-like cells were analyzed using flow cytometry in a cohort of 49 MDS patients, including transformed and non-transformed groups.
Results
A non-hematopoietic CD13-bright cell population, enriched for MSC markers CD105 and CD90, was identified in 80% of patients at diagnosis. Elevated of these MSC-like cells were significantly associated with earlier progression to leukemia and reduced overall survival. Multivariate analysis confirmed MSC content as an independent predictor of leukemia transformation.
Conclusion
MSC-like cell content at MDS diagnosis may serve as a novel biomarker of predicting malignant transformation to AML. Further validation in larger cohorts and better phenotypic characterization of this cell population are needed.
Trial Registration
The authors have confirmed clinical trial registration is not needed for this submission
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
